
Three-dimensional cell culture approach for in vitro immunization and the production of monoclonal antibodies
Author(s) -
Robert Engel,
Burkhard Micheel,
Katja Hanack
Publication year - 2022
Publication title -
biomedical materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.744
H-Index - 72
eISSN - 1748-605X
pISSN - 1748-6041
DOI - 10.1088/1748-605x/ac7b00
Subject(s) - monoclonal antibody , dispase , antigen , hybridoma technology , antibody , cell culture , microbiology and biotechnology , in vitro , biology , immunology , biochemistry , genetics , collagenase , enzyme
The generation of monoclonal antibodies using an in vitro immunization approach is a promising alternative to conventional hybridoma technology. As recently published, the in vitro approach enables an antigen-specific activation of B lymphocytes within 10-12 d followed by immortalization and subsequent selection of hybridomas. This in vitro process can be further improved by using a three-dimensional surrounding to stabilize the complex microenvironment required for a successful immune reaction. In this study, the suitability of Geltrex as a material for the generation of monoclonal antigen-specific antibodies by in vitro immunization was analyzed. We could show that dendritic cells, B cells, and T cells were able to travel through and interact inside of the matrix, leading to the antigen-specific activation of T and B cells. For cell recovery and subsequent hybridoma technique the suitability of dispase and Corning cell recovery solution (CRS) was compared. In our experiments, the use of dispase resulted in a severe alteration of cell surface receptor expression patterns and significantly higher cell death, while we could not detect an adverse effect of Corning CRS. Finally, an easy approach for high-density cell culture was established by printing an alginate ring inside a cell culture vessel. The ring was filled with Geltrex, cells, and medium to ensure a sufficient supply during cultivation. Using this approach, we were able to generate monoclonal hybridomas that produce antigen-specific antibodies against ovalbumin and the SARS-CoV-2 nucleocapsid protein.